Rifampicin, Isoniazid & Ethambutol Tablets – RHE FDC Manufacturer India

1. Product Introduction

Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as exporter of Rifampicin, Isoniazid and Ethambutol Hydrochloride Tablets. This triple fixed-dose combination (RHE) contains three antituberculosis agents in a single film-coated tablet, supporting simplified administration when the combination is appropriate for a prescribed TB regimen.

RHE is not interchangeable with the standard four-drug RHZE intensive-phase regimen and must not be presented as a universal continuation-phase regimen. Selection depends on susceptibility results, treatment history, local TB programme guidance and clinical factors. Manufacturing capabilities, WHO-GMP status, registration and export supply should be confirmed with current documents.

2. Product Specifications

3. Manufacturing Technology

Formulation considerations: Rifampicin stability and compatibility with isoniazid, together with moisture control for ethambutol hydrochloride, require careful excipient selection and validated processing. Barrier granulation, separated layers or other technologies may be evaluated, but the exact technology used for this product has not been verified.

Packaging: Moisture-resistant, validated packaging and appropriate stability studies are important for tropical distribution. Patient kits, bilayer/trilayer construction and particular humidity specifications should be confirmed against actual manufacturing records before publication as established capabilities.

4. Quality Assurance

Each batch should be assessed against the applicable approved pharmacopoeial and registration specifications, including identity, assay, content uniformity, dissolution for each active ingredient, related substances, microbial quality where applicable, and packaging integrity.

Particular attention is required for rifampicin degradation and potential interactions among active ingredients. Numerical assay, dissolution and impurity limits must be taken from the current validated monograph and registered product specification; unverified universal limits should not be claimed.

5. Mechanism and Therapeutic Uses

Rifampicin inhibits bacterial DNA-dependent RNA polymerase; isoniazid inhibits mycolic-acid synthesis; and ethambutol interferes with mycobacterial cell-wall arabinan synthesis.

The combination may be used in selected Mycobacterium tuberculosis treatment regimens when supported by national or international guidelines and drug-susceptibility information. It is not appropriate to assume efficacy against rifampicin-resistant or multidrug-resistant TB. The treating TB specialist determines the complete regimen and treatment phase.

6. Export and Regulatory Support

For B2B procurement, request current manufacturing licences, product registration status, WHO-GMP evidence where applicable, certificate of analysis, validated stability data, packaging specifications and regulatory dossier availability. CTD/ACTD, COPP, FSC, tender eligibility, destination-market authorisations and shipment terms should be confirmed individually rather than assumed.

7. Frequently Asked Questions

Q: What is the composition of one RHE tablet?
A: Rifampicin 150 mg, Isoniazid 75 mg and Ethambutol HCl 275 mg, in a film-coated tablet.

Q: Can RHE replace standard TB treatment?
A: No. It is used only where a qualified clinician selects an appropriate combination regimen based on applicable guidelines and susceptibility.

Q: Can ethambutol affect vision?
A: Yes. Changes in visual acuity or red-green colour discrimination need urgent clinical assessment.

Q: Does rifampicin change urine colour?
A: Orange-red discoloration of urine, tears and other body fluids is expected; however, other concerning symptoms should be assessed.

8. Dosage and Administration

Prescription use only. Tablet count, frequency, treatment duration and whether additional drugs are needed depend on body-weight band, age, organ function, drug susceptibility and the applicable national TB protocol. A fixed number of tablets is not suitable for every adult.

Follow the prescriber's administration instructions and the approved label. Rifampicin-containing regimens often have food-related instructions, but these must be balanced with tolerability and product-specific guidance. Do not interrupt treatment or use a partial regimen without specialist advice.

9. Side Effects and Precautions

• Ethambutol: Optic neuropathy; baseline and follow-up visual assessment may be needed. Promptly report blurred vision or colour-vision changes.
• Rifampicin and isoniazid: Hepatotoxicity; seek medical advice for jaundice, persistent vomiting, marked fatigue or dark urine. Monitor liver function as clinically indicated.
• Isoniazid: Peripheral neuropathy; pyridoxine supplementation is recommended for patients at risk according to treatment guidelines.
• Rifampicin: Important drug interactions, including with some antiretrovirals, anticoagulants and hormonal contraceptives; medication review is essential.
• Resistance: Treatment must follow appropriate susceptibility testing and an effective multidrug regimen.

10. Storage Instructions

Store as directed on the approved product label, protected from moisture and excessive heat, in the original container or blister until use. Exact temperature limits and shelf life must be supported by the registered label and stability data. Keep out of reach of children.